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The development of effective meningococcal vaccines was based upon the finding that
natural immunity to the meningococcus was directly correlated with serum bactericidal anti-
bodies. Purified high molecular weight capsular polysaccharides of serogroups A and C me-
ningococci stimulated the production of humoral antibodies which had group specific bacteri-
cidal activity. In controlled field trials in Army recruits, group C polysaccharide vaccines were
highly effective in preventing group C disease. Following its use as a routine immunization in
recruits in October 1971 group C meningococcal disease has been almost completely elim-
inated from Army training centers. Group A vaccine has been field tested in Egyptian school
children with great success. Group B polysaccharide has failed to induce bactericidal anti-
bodies in humans and, therefore, new research is underway to attempt to develop a cell wall
protein antigen as a vaccine against group B disease.
Epidemic meningococcal meningitis has been a serious medical problem during
every major military mobilization of the United States in this century. Attempts at
control of the disease by nonspecific measures such as environmental manipulation
(isolation of infected patients or reducing crowding in barracks) have not met with
general success (1). Reduction of person-to-person transmission by means of sulfo-
namide chemoprophylaxis provided rather spectacular control of epidemics for al-
most 20 yr until the emergence and spread of sulfonamide resistant strains begin-
ning in 1963 (2). Subsequent intensive research has led to thedevelopment and use of
meningococcal polysaccharide vaccines which will be summarized in this report.
BACTERIOLOGY, IMMUNOLOGY, AND PATHOPHYSIOLOGY OF
Neisseria Meningitidis
Neisseria meningitidis, also termed the meningococcus, is a bacterial species of
the genus Neisseria, which is characterized by its diplococcal morphology, Gram's
stain negative reaction, the presence of the enzyme oxidase, and the typical oxi-
dation of both dextrose and maltose. Meningococci are divided into serogroups on
the basis of agglutination with antisera. At least nine distinct groups are recognized
of which serogroups A, B, C, and Y are the most prevalent. Two distinct patterns of
human infection are recognized: (1) the nasopharyngeal carrier state which is almost
always asymptomatic and which may persist for weeks to years and (2) systemic in-
fection ofwhich meningitis and/or septicemia are the most frequent manifestations.
Two factors are probably involved in determining whether serious disease occurs
following acquisition ofthe organism in the upper respiratory tract. Virulence ofthe
infecting strain is one aspect but cannot be further defined since laboratory and
animal models for its study are not available. The other major factor is the state of
natural immunity of the host. The studies ofGoldschneider, Gotschlich, and Arten-
stein (3) have clarified to some extent the manner in which human immunity de-
velops. They found that immunity correlated directly with the presence ofhumoral
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bactericidal antibodies against meningococci. These antibodies were present in the
blood of newborn infants, fell to a low level by age 6 mo, and were lowest at age 12
mo. After this an increasing prevalence was detected with increasing age reaching
peak prevalence in young adults in whom 67-87% had antibodies to the major
disease producing serogroups A, B, and C. Disease incidence correlated inversely
with the presence of bactericidal antibodies; the peak disease incidence occurring at
age 12 mo.
Meningococcal Antigens
Those antigens of greatest interest in terms of vaccines are found in the capsule
and cell wall of the meningococcus. The capsules consist of polymers of amino
sugars which have been chemically identified as N-acetyl-mannosamine-phosphate
(group A), N-acetyl neuraminic acid (group B), and N-acetyl, O-acetyl neuraminic
acid (group C). Each of these polysaccharides has been extracted in high molecular
weight form and has been highly purified (4). Antibodies directed against these cap-
sular antigens are serogroup specific. Cell wall proteins and lipopolysaccharides
(LPS) have also been separated and purified (5). The protein antigens show some
sharing among the various serogroups but, nevertheless, systems of subtyping of
meningococci have been developed which are based upon these antigens (6, 7). LPS,
in addition to having antigenic properties (8), is also the endotoxin of the organism
and, thus, is responsible for many of the severe clinical features of the disease such
as purpura and shock. Of interest, protein and LPS antigens of meningococci
crossreact with gonococcal antigens (9).
Development and Use ofMeningococcal Vaccines
Purified, high molecular weight group A and C polysaccharides, although nonim-
munogenic in laboratory animals, were highly active in inducing antibody responses
in humans (10). A single, parenteral injection of 50 ,ug quantity produced antibody
response in 90-100% of subjects without evidence oftoxic sideeffects. Antibodies in-
duced by vaccines were measured by a variety oftechniques and, significantly, bacte-
ricidal antibodies were formed (10). The bactericidal antibodies were serogroup
specific. After a number of preliminary studies which demonstrated safety, optimal
dose, and route ofinjection (11), large-scale field studies were initiated with group C
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FIG. 1. Meningococcal meningitis. U. S. Army cases by serogroup and year. Data based upon strains
submitted to Walter Reed Army Institute of Research for confirmation.
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TABLE 1
Field Trials of Group C Meningococcal Polysaccharide Vaccinesa
Vaccine group Control group
No. of cases No. of cases
and serogroup and serogroup
Year No. of men B C No. of men B C
1969 1 3,763 4 1 54,309 3 38
1969-1970 14,482 0 1 60,172 0 35
Totals 28,245 4 2 114,481 3 73
aData compiled from references (12) and (13).
vaccine because of the high incidence of group C disease in Army recruit training
centers (12,13). The results of these studies are summarized in Table 1. In vac-
cinated men the attack rate ofgroup C disease was reduced to 89% of that observed
in the control group. However, the number of illnesses caused by group B menin-
gococci was greater in men who received C polysaccharide than in nonvaccinated
controls. Following the demonstration of the safety and efficacy of this vaccine
routine immunization in Army and Navy training centers was instituted in the Fall
of 1971 and somewhat later in Air Force trainees. The impact of this immunization
has been quite striking in that reported cases of meningococcal disease have fallen
and remained at levels less than one-tenth those previously observed (Fig. 1). Al-
though the specificity of the antibody response (10) and the failure of the group C
vaccine to prevent illness due to other serogroups (Table 1) were a source of some
concern, there has been no evidence of the emergence ofgroup B or group Y disease
as an epidemic threat. Nevertheless this possibility still exists and Army menin-
gococcal case rates must be closely watched.
Group A vaccines could not be field tested in the United States since this
organism has only rarely been isolated here in the past decade. Trials carried out in
Egyptian school children by the World Health Organization with assistance from
U. S. Navy research scientists have shown the group A vaccine to be highly effective
in preventing group A disease (14).
Recent studies by the Walter Reed Army Institute of Research Laboratory have
shown that group C antibodies induced by vaccination persist at nearly the early
peak levels for a period of at least 5 yr (15). From these data it is inferred that im-
munity will also be long-lasting.
Group B polysaccharide vaccines have been prepared and tested in several
hundred volunteers but very few subjects showed antibody response (16). The
reasons for this lack of immunogenicity are not understood. An alternative ap-
proach to a group B vaccine is now under study at Walter Reed; namely, to utilize
purified cell wall protein antigens. Should these be effective it might be possible to
combine the protein vaccine with polysaccharides to encompass the three major
pathogenic serogroups in one vaccine.
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